CD99 reactivity in mesenchymal chondrosarcoma

CD99 reactivity has been reported to be a sensitive and specific marker for Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET). However, within the group of “small round blue cell tumors,” the specificity has not been extensively examined. We investigated the immunoreactivity of me...

Full description

Saved in:
Bibliographic Details
Published in:Human pathology 1996-12, Vol.27 (12), p.1273-1276
Main Authors: Granter, Scott R, Renshaw, Andrew A, Fletcher, Christopher D.M, Bhan, Atul K, Rosenberg, Andrew E
Format: Article
Language:English
Subjects:
12E7 Antigen
Adolescent
Adult
Antigens, CD - analysis
Biological and medical sciences
Bone Neoplasms - immunology
Cartilage - immunology
Cartilage - pathology
CD99
Cell Adhesion Molecules - analysis
Chondrosarcoma, Mesenchymal - immunology
Diseases of the osteoarticular system
Ewing's sarcoma
Female
Head and Neck Neoplasms - immunology
Humans
Immunohistochemistry
Male
Medical sciences
mesenchymal chondrosarcoma
MIC2
Middle Aged
primitive neuroectodermal tumors
Soft Tissue Neoplasms - immunology
Tumors of striated muscle and skeleton
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CD99 reactivity has been reported to be a sensitive and specific marker for Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET). However, within the group of “small round blue cell tumors,” the specificity has not been extensively examined. We investigated the immunoreactivity of mesenchymal chondrosarcoma to CD99 using the 013 antibody and found reactivity in 11 of 11 (100%) of cases, specifically in the “small round blue cell” component. All cases showed strong reactivity involving more than 50% of the small round blue cells with a distinct membrane pattern of staining. Staining was either absent or focal and weak in cartilaginous areas. We conclude that mesenchymal chondrosarcoma cannot be distinguished from ES/PNET on the basis of CD99 immunoreactivity.
ISSN:0046-8177
1532-8392
DOI:10.1016/S0046-8177(96)90336-6